David Henry's JCSO Podcast

David Henry's JCSO podcast, March 2015


 

References

In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.

Recommended Reading

Nurses’ Health Study: No link between depression and breast cancer
MDedge Hematology and Oncology
Supreme Court won’t hear IPAB challenge
MDedge Hematology and Oncology
FDA strengthens allergy warning for IV anemia therapy ferumoxytol
MDedge Hematology and Oncology
Physician-patient communication, terminology play important role in CPM decisions
MDedge Hematology and Oncology
Gynecologic cancers predict coexisting pelvic floor disorders
MDedge Hematology and Oncology
Engineered protein overcomes radiation resistance in ALL
MDedge Hematology and Oncology
FDA strengthens warnings for anemia drug
MDedge Hematology and Oncology
Findings may aid development of antithrombotic drugs
MDedge Hematology and Oncology
Compounds could treat MLL leukemia
MDedge Hematology and Oncology
Increasing cell signaling to eradicate Ph+ ALL
MDedge Hematology and Oncology